ArticleMolecular neurobiology2025
Evaluating the Protective Effects of Silymarin Along with a Cholesterol-Supplemented Diet Against Demyelination in an EAE Mouse Model of Multiple Sclerosis: Lipidomic and Inflammatory Aspects.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Demyelination in multiple sclerosis (MS) is associated with chronic inflammation and dysregulation of cholesterol metabolism. In this study, we investigated the protective effects of silymarin, an herbal flavonoid, against inflammation, impairment of brain cholesterol metabolism, and demyelination in the experimental autoimmune encephalomyelitis (EAE) model of MS. Given the well-documented anti-hypercholesterolemic properties of silymarin, we sought to assess its protective effects in combination with a cholesterol-supplemented diet. Additionally, the effects of the cholesterol-supplemented diet alone were evaluated. Female C57BL/6 mice were fed either a standard chow diet or a cholesterol-supplemented standard chow for 2 weeks prior to EAE induction, continuing until day 20 post-immunization. Experimental groups received silymarin, a cholesterol-supplemented diet, or both treatments. Silymarin significantly reduced clinical symptoms and the incidence of EAE, alleviated inflammation, prevented severe demyelination, modulated the expression genes involved in brain cholesterol metabolism, and ultimately improved the serum lipid profile. The cholesterol-supplemented diet alone was partially effective. Co-administration of silymarin with the cholesterol-supplemented diet showed superior efficacy across some outcomes. String web analysis revealed the significant interaction of apolipoprotein E (ApoE), a major component of brain HDL-like particles, with other key genes. ELISA results demonstrated that silymarin alone and in combination with the cholesterol-supplemented diet restored ApoE levels in EAE-induced mice. These findings suggest that silymarin, in conjunction with a cholesterol-supplemented diet, warrants further investigation in clinical trials as a potential protective strategy for MS management.
Indexed as
Identifiers
40193019What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.